sdbn.org

News, Syndication, Xconomy »

Who’s on Biotech’s Endangered Species List? Mid-Sized Drug Developers
Posted by sandiegobiotech May 21st, 2012 .
No Comments

Only a few companies have ever been successful enough to call themselves Big Biotechs. If boards and shareholders lack vision and guts, we’ll look back in few years and wonder why the Big Biotechs...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Who’s on Biotech’s Endangered Species List? Mid-Sized Drugmakers
Posted by sandiegobiotech May 21st, 2012 .
No Comments

Only a few companies have ever been successful enough to call themselves Big Biotechs. If boards and shareholders lack vision and guts, we’ll look back in a few years and wonder why the Big Biotechs...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

For Those on Watch, Hope Springs Eternal as Hair Trials Inch Along
Posted by sandiegobiotech May 18th, 2012 .
No Comments

Waiting for the biotech industry to advance new treatments for male pattern baldness (as well as female hair loss) might seem about as exciting as watching hair grow. But some people have a lot of...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

For Those on Watch, Hope Springs Eternal as Hair Trials Inch Along
Posted by sandiegobiotech May 18th, 2012 .
No Comments

Waiting for the biotech industry to advance new treatments for male pattern baldness (as well as female hair loss) might seem about as exciting as watching hair grow. But some people have a lot of...

[[Click headline to continue reading.]] More...

Drug Development, News, Syndication, Xconomy »

SD Biotech Roundup: Elevation Pharmaceuticals, BioSurplus, and More
Posted by sandiegobiotech May 17th, 2012 .
No Comments

We’re anticipating a lot of news out of a big cancer conference that begins next week in Chicago. Here is your head start. —Cancer researchers have talked for decades about finding the silver bullet...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Xconomist of the Week: Tom Maniatis on Prize4Life and ALS Research
Posted by sandiegobiotech May 17th, 2012 .
No Comments

A few years back, molecular geneticist Tom Maniatis was approached by a Harvard Business School student with a heart-wrenching story. The student, Avichai Kremer, then 29, had been diagnosed with...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Targeted Cancer Drugs With Punch: The Next Big Class of Antibodies
Posted by sandiegobiotech May 16th, 2012 .
No Comments

[Updated: 1:30 pm PT, 5/17/12] One of the big dreams in biotech over the past 35 years has been to make drugs that work like “smart bombs” by destroying tumors while minimizing collateral damage....

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

ASCO Preview: Eight Cancer Drugs to Watch at the Big Show
Posted by sandiegobiotech May 14th, 2012 .
No Comments

The pistons of the biggest publicity engine in cancer R&D will start firing this week. It’s time to behold the annual rite of the American Society of Clinical Oncology (ASCO) meeting, the biggest...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

SD Life Sciences Roundup: Celladon, Vertex, MediciNova, & More
Posted by sandiegobiotech May 10th, 2012 .
No Comments

Massachusetts’ Vertex and San Diego’s Celladon are advancing some promising gene therapy treatments. Here’s our roundup of life sciences news over the past week. —San Diego’s Celladon, which is...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

A 10-Point Plan to Stimulate Biotech & the Economy as a Whole
Posted by sandiegobiotech May 9th, 2012 .
No Comments

AN OPEN LETTER TO PRESIDENT OBAMA Dear President Obama: As you and the rest of our nation’s leadership grapple with the momentous questions of restoring our collective financial stability and...

[[Click headline to continue reading.]] More...